


# WHITE PAPER



## **Vitamin C Foundation Oral Dosage Recommendations to Achieve CSC-Lethal Concentrations of Ascorbate**

This information is new and this document should be shared with your oncologist and other professional care-givers. The Vitamin C Foundation, believes on the weight of the existing science, that vitamin C can complement conventional cancer treatments, such as chemotherapy and radiation, i.e., vitamin C can help cancer patients live longer and feel better while undergoing conventional therapy. This new information, based on both first-time ever *in vitro* research, and a xenograft experiment in live mice, the best ever with a reported 40% reduction in pancreate tumor size, suggests optimal vitamin C dosing. After your doctors have been informed, and are given time to study the new research, we strongly suggest you follow their advice and guidance.

© Copyright 2017 The Vitamin C Foundation. *Permission to reproduce and distribute freely granted with minor grammar edits so long as content is maintained.*

**A 1 g oral dose of Ascorbic Acid (AA) can raise plasma AA to 130  $\mu\text{mol/L}$  within an hour and such doses at intervals of about two hours throughout the day can maintain  $\sim 230 \mu\text{mol AA/L}$**

Cheryl A Krone, John A Ely, Journal of the New Zealand Medical Association, 23-August-2002, Vol 115 No 1160, Glycohaemoglobin and ascorbic acid)

This White Paper assigns oral vitamin C dosages to the optimal numbers found in the landmark Sen, *et. al.* study ***Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs)***

<http://onlinelibrary.wiley.com/doi/10.1002/cbin.10830/full>

### **Basic Vitamin C Oral Dosing Recommendation for Cancer Patients**

Vitamin C in a daily dosage of **1,000 mg (1 gram) or less** would create the concentrations that cause CSC proliferation ( $5$  to  $25 \mu\text{M/L}$ ) and should be avoided by cancer patients.

**Supplement vitamin C, at least 1 gram every 2 hours**, as often as possible, no matter what other cancer therapies you are on. ( $12,000 \text{ mg}$  or  $12 \text{ g per day}$ ) to maintain a blood level about  $100 \mu\text{M/L}$ .

Higher doses, e.g. **2 or 4 grams every 3 to 4 hours** would be even more optimal. ( $16,000 \text{ mg}$  –  $24,000 \text{ mg}$  ( $16 \text{ g}$  -  $24 \text{ g}$ ) per day.)

**The highest dosages, up to 40 to 80 g per day of vitamin C** should maintain the highest optimal CSC killing range studied by Sen, *et. al.*

Even higher vitamin C dosages are being investigated intravenously (Drisko), but their optimality w/r to CSCs was not investigated by Sen, and may be contraindicated.



### **Bottom Line: Oral Vitamin C Dosages Can Achieve Cancer Stem Cell (CSC) Destruction to Avoid Colon Cancer Stem Cell Proliferation.**

For the first time in the history of science a group of researchers in India have studied the optimal dosing of vitamin C with respect to the "seeds of cancer," i.e., colon cancer stem cells (CSCs). Sen, *et. al.*, found that higher doses of vitamin C and Niacin, or vitamin B3, destroy cancer stem cells.

About a decade ago, a leading US cancer center at the University of Michigan issued a release that conventional therapies are targeting only one type of class of cancer cell - ordinary, rapidly dividing malignant cancer cells, but that cancers emanate from seed cells, or cancer stem cells (CSCs). Since then we've noticed in the recent news stories and studies, especially from Europe, a focus on Cancer Stem Cells because these cells do not divide rapidly enough for chemo and radiation to kill them. If CSCs proliferate, their progeny becomes even stronger malignant cancer cells.

When you are fighting cancer - you are fighting both enemies.

The new, first-ever study found that vitamin C, and Niacin, at the proper concentrations can KILL these CSCs - the seeds of ordinary malignant cells. But that too small concentrations of vitamin C (and Niacin) actually promote the proliferation of these cancer-seed cells. There are two different types of cancerous cells, and they are killed differently.

Published in the journal *Cell Biology International*, the landmark study investigated both low and high doses of vitamin C and Niacin on stem cells tumors of the intestine. Different dosages produced opposite effects.

#### Study Abstract

Colorectal cancer is one of the global causes of cancer deaths. Cancer stem cells (CSCs) inside the tumour niche responsible for metastasis and relapses, and hence need to be targeted for cancer therapeutics. Although dietary fibre and lifestyle changes have been recommended as measures for colorectal cancer prevention, no such recommendations are available for using water soluble vitamins as prophylaxis measure for colorectal cancers. High dose of Vitamin C has been proven to selectively kill colon cancer cells having BRAF and KRAS mutations by inducing oxidative stress. In this study, we show for the first time the opposing effects of the low and high dose of Vitamin C and vitamin B3 on colon CSCs isolated from HT-29 and HCT-15 colorectal carcinoma cell lines. At small doses, both of these vitamins exerted a cell proliferative effect only on CSCs, while there was no change in the proliferation status of non-stem cancer cells and wild-type (WT) populations. On the other hand, the death effects induced by high doses of Vitamin C and B3 were of the order of 50-60% and ~30% on CSCs from HT-29 and HCT15, respectively. Interestingly, the control fibroblast cell line (NIH3T3) was highly refractory all the tested concentrations of Vitamin C and B3, except for the highest dose - 10,000 µg of Vitamin C that induced only 15% of cell death. Hence, these results indicate the future scope of use of therapeutic doses of Vitamin C and B3 especially in patients with advanced colorectal cancer.

If this landmark test tube research translates into *in vivo* blood concentrations in humans, we now know that when taking vitamin C to create a blood concentration of 5-25 micromole/L of vitamins C and B3, which is a low concentration, there is a process of active reproduction of stem cells tumors of the intestine. At high dosages (creating concentrations of 100 to 1,000 micromoles/L) these stem cells are destroyed. Higher dosages, e.g. 10,000 micromoles/L caused renewed CSC proliferation.

A new major British epidemiological (*in vivo*) study with a cohort of 38,812 was just published (Egnell, 2017). This large study found that increased dietary levels of antioxidants such as vitamin C, E, β-carotene, and selenium are associated with lower risk of developing colon cancer. On the basis of the evidence, the authors wrote: “Healthcare professionals may promote intake of these antioxidants in healthy amounts in order to reduce the incidence of this type of malignancy.”

There is no known harm or toxicity from taking vitamin C, so there is no reason for cancer patients to wait for more studies.

The next table from the Sen *et. al.*, study shows relative proliferation based on dosage of vitamin C. (There is a similar table in the study showing the proliferation rates for Niacin.) Numbers above 100 indicate proliferation, while numbers less than 100 indicate apoptosis or cell death.

**Table 2. Percentage of cell proliferation upon exposure to low (5–25 μM) and high concentration ranges (100–10,000 μM) of vitamin C/ascorbic acid in various cell populations obtained from HT-29 and HCT-15 colorectal carcinoma cell lines respectively.** Table showing the respective percentages of cell proliferation of the cell populations WT, CSCs (CD44<sup>+</sup>) and non-stem cancer cells (CD44<sup>-</sup>) with respect to various concentrations (5–10,000 μM) of Vitamin C/Vitamin C from HT-29 and HCT-15 cell lines. The untreated control cells for each of the cell type WT, CSCs (CD44<sup>+</sup>) and non-stem cancer cells (CD44<sup>-</sup>) have been assigned an arbitrary value of 100% cell proliferation

Cell types and percentage of cell proliferation						
Vitamin C conc. μM	HT-29 WT	HCT-15 WT	HT-29- CD44 <sup>+</sup>	HCT-15 CD44 <sup>+</sup>	HT-29- CD44 <sup>-</sup>	HCT-15 CD44 <sup>-</sup>
0	100	100	100	100	100	100
5	114	108	172	107	86	122
10	104.7	114	160.8	107.26	93.11	121.01
15	95.81	121.03	172	110.15	97.1	106
20	90.57	94.19	169.73	115.01	99.2	93.79
25	88.48	90.01	169.73	116.32	86.59	98.13
100	21.51	89.01	68.28	93.79	14.23	96.15
200	21.81	88.06	69.34	73.58	14.13	96.52
500	23.56	85.42	67.23	72.01	12.68	95.16
1,000	24.34	83.12	65.81	69.56	11.59	88.06
10,000	27.06	226	61.18	304.10	14.13	233.03

**The Vitamin C Foundation nonprofit recommends that on the basis of the Sen, *et. al.* landmark study, all cancer patients be advised to supplement vitamin C in oral amounts that can achieve at least a 100 micromoles/liter concentration in their blood for as long as possible.**

The major problem is that the kidney constantly reduces vitamin C concentrations to less than this amount steady state, e.g. 85 micromoles/liter, with a half-life of 30 minutes. **Our initial estimates are that 1 gram or less of oral vitamin C daily creates the concentrations that promote CSC proliferation,** and that 4 grams creates the minimum required 100 micromole/liter concentration, at least for a little while. If this work translates, dosages up to 80 grams would be appropriate and safe.

## **Continuous Oral Dosing May Work Better than Intravenous Vitamin C**

The Vitamin C Foundation calculates that continuous oral supplemental oral intakes of vitamin C can achieve the study's reported cancer-lethal concentrations in the blood. The normal laboratory range for vitamin C in the USA is 0.4 mg/dl to 1.5 mg/dl, (23 to 85  $\mu\text{M/L}$ ). The Indian study results indicate that a 100  $\mu\text{M}$  concentration (1.76 mg/dl) is the low end of the cancer-lethal range, or just above steady state (1.5 mg/dl). Sustaining this above-steady state blood level requires continuous vitamin C supplementation, as long advocated by vitamin C experts Steve Hickey and Hilary Roberts, PhDs.

While intravenous vitamin C can exceed the 10,000  $\mu\text{M}$  by 2.5 times (e.g. 440 mg/dl or 24,983.2  $\mu\text{M/L}$ ) this level was not investigated, may be suboptimal spurring CSC proliferation, and it is difficult to keep people on constant intravenous vitamin C infusions.

The low range (5 to 25  $\mu\text{M}$ ) that promotes the growth of cancer stem cells equals a lab range of 0.08 to 0.44 mg/dl which is below normal and can easily be raised through regular vitamin C supplementation.

*Note: The Sen, et. al., measurements indicate that daily amounts of one gram or less of vitamin C promote CSC proliferation. This new finding indicates that the government approved RDA for Vitamin C, and the low amount currently recommended by the Linus Pauling Institute at Oregon State, are dangerous for cancer patients. Much more vitamin C is needed to avoid CSC proliferation and malignancy relapse, at least 12 grams daily as long recommended by Linus Pauling.*



### ***I Have Cancer, How Much Vitamin C Should I Take Based on The Sen, et. al. Test Tube Study?***

On the basis of research conducted in New Zealand, (Krone/Ely 2002) we believe that **the minimum dosage to maintain a cancer-killing concentration is 1,000 mg every 2 hours.**

**A 1 g oral dose of AA can raise plasma AA to 130  $\mu\text{mol/L}$  within an hour and such doses at intervals of about two hours throughout the day can maintain  $\sim 230$   $\mu\text{mol AA/L}$**

***Self-reported daily intake varied from 0 to 20 g/day. The plasma AA levels ranged from 11.4 to 517  $\mu\text{mol/L}$  and correlated well with the reported intake.***

Cheryl A Krone, John A Ely, Journal of the New Zealand Medical Association, 23-August-2002, Vol 115 No 1160, Glycohaemoglobin and ascorbic acid)

**The 1 gram/2 hour minimum protocol requires a daily dosage of 12,000 milligram (12 grams)**

*Note: 8 hours of sleep requires a loading dose before bed, or timed release vitamin C. This minimum oral protocol maintains a 230  $\mu\text{M}$  concentration, which is at the low-end of the optimum cancer killing range (100 $\mu\text{M}$  to 1,000 $\mu\text{M}$ )*

Sen, *et. al.* did not investigate the mid-range vitamin C concentrations, from 26  $\mu\text{M}$  to 99  $\mu\text{M}$ .

The low, CSC stimulating concentrations (<26 $\mu\text{M}$ ) would be expected from taking 1,000 mg (1 gram) of vitamin C or less daily.

We calculate that without the short half-life, approximately 40,000 mg (40 grams) of Vitamin C daily would reach a maximum optimal concentration of 1,000  $\mu\text{M}$ . But high levels of vitamin C do not remain in the blood. Because of the short 30-minute half-life, we believe that 80 grams of vitamin C would be safe, and achieve the 1,000  $\mu\text{M}$  concentration, on average, over a longer duration.

It is believed that conventional therapies destroy ordinary aggressive malignancies by creating oxidative stress. Very high dose vitamin C does produce hydrogen peroxide by overcoming enzyme system (e.g. catalyze) that would otherwise prevent this. As the Sen, *et. al.*, abstract points out, IV/C. has been proven to treat ordinary cancer cells by creating oxidative stress. Therefore, rather than stopping vitamin C during conventional chemotherapy and/or radiation, increasing the dosage using very high dose IV/C may provide better results in conjunction with these therapies. Drisko is currently researching 200 gram IV/C in conjunction with conventional therapies.

The Vitamin C Foundation is not competent to assign Vitamin B3 (Niacin) dosing values based on the Sen, *et. al.* Study. Niacin was about 50% as effective as vitamin C killing Cancer Stem Cells (CSCs). However, we note that Vitamin B3 expert A. Hoffer, MD, PhD, in his book *Vitamin C and Cancer: Discovery, Recovery, Controversy (2000)* reported excellent results prescribing equal amounts of vitamin C and Niacin to cancer patients.



## **Discussion**

Many factors can affect ascorbate (vitamin C) blood concentrations, including the short 30-minute half-life, stress and illness, the type of vitamin C that is taken orally (e.g. ascorbic acid versus sodium ascorbate or liposomal vitamin C), the amount of sugar (glucose) in the diet, and the ability of the patient to consume high amounts of vitamin C, often called Bowel Tolerance.

In 1976, biochemist Sherry Lewin, PhD reported in her book *VITAMIN C: Its Biology and Medical Potential* that when vitamin C is administered at the same time carbohydrates are eaten, the vitamin breaks down in the intestinal tract, and less is absorbed into the blood stream. In contrast, when vitamin C is eaten with a protein, the amino acids chelate with the vitamin, protecting it during digestion, making the vitamin more bioavailable. There are many products on the market that offer both vitamin C and the amino acid lysine together.

The Vitamin C Foundation's recently published *BIOAVAILABILITY OF VITAMIN C* paper in the Townsend Letter for Doctors and Patients is based on original research. The Foundation demonstrated the different rates of absorption between ascorbic acid, and the salt sodium ascorbate. Previously unknown, ascorbic acid entry into the blood stream is very rapid, probably through the stomach wall, and concentrations can exceed an IV/C, at least for a short time. On the other hand, sodium ascorbate enters the blood stream more slowly, more like a timed release, and probably travels down the GI Tract and is absorbed through the intestines. If sodium ascorbate is not taken with protein, it is probable that more of the vitamin would break down and not be bioavailable in the form of sodium ascorbate, indicating that a higher dosage may be required.

Some people have low bowel tolerances, meaning they cannot achieve even the minimum daily protocol of 1 gram every 2 hours. Liposomal technology may be the answer because more vitamin C is absorbed when encapsulated in liposomes, and the liposomes persist 4 to 6 times longer in the blood stream. It is unknown whether the vitamin encased in a 150 nanometer liposome would have the same CSC killing effect. Sen reports on a study that found liposomes made from fat soluble vitamin C (ascorbyl palimate) were more potent than ordinary vitamin C injections in breast cancers.

**However, intravenous administration of palmitoyl ascorbate liposomes proved to be more potent, as compared to, free Vitamin C injection in Balb/c mice model of mammary carcinoma (Sawant et al., 2012).**

Sawant RR, Vaze OS, Wang T, D'Souza GG, Rockwell K, Gada K, Torchilin VP (2012) Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration. Pharm Res 29(2): 375–83.



## ***Dosing Summary***

Our advice to all cancer patients: Supplement vitamin C, at least 1 gram every 2 hours, no matter what other therapies you are on. (12,000 mg or 12 g per day)

Do supplement vitamin C, and do not supplement less than one gram per day.

Higher doses, e.g. 2 or 4 grams every 3 to 4 hours would be even more optimal. 16,000 mg (16 g) to 24,000 mg (24 g) per day.

The highest dosages, up to 40 to 80 g per day should maintain the highest optimal CSC killing range.

This confirms Dr. Robert's Cathcart, II, MD's clinical experience that the bowel tolerance range for cancer patients is a daily amount 15 g to 100 g

[https://vitaminfoundation.org/FDAapproved/pdfs/Vitamin\\_C\\_Dosage\\_in\\_Disease.pdf](https://vitaminfoundation.org/FDAapproved/pdfs/Vitamin_C_Dosage_in_Disease.pdf)

While much higher dosages are being investigated intravenously (Drisko), the optimality of these



dosage w/r to CSCs was not investigated by Sen. These high doses create oxidative stress in or near cancer cells, which may enhance conventional therapies.

It is interesting that the 12,000 grams of vitamin C would also achieve Linus Pauling's recommended therapeutic dosages for cardiovascular disease.

## References

*Daniel Couturier wrote: "I cannot comprehend why even proponents of high dose vitamin C consider it to be an inferior resource when it comes to antagonizing malignancies, considering the fact that available studies indicate that at doses of 4 g / kg b.w. a pancreatic tumor mass reduction of more than 40% could be achieved in a xenograft animal model. "*

Proc Natl Acad Sci U S A. 2008 Aug 12; 105(32): 11105–11109.

Published online 2008 Aug 4. doi: 10.1073/pnas.0804226105

PMCID: PMC2516281

### **Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice**

Qi Chen,\*† Michael Graham Espey,\*†‡ Andrew Y. Sun,\* Chaya Poooput,§ Kenneth L. Kirk,§ Murali C. Krishna,¶|| Deena Beneda Khosh,|| Jeanne Drisko,|| and Mark Levine\*‡

#### Abstract

Ascorbic acid is an essential nutrient commonly regarded as an antioxidant. In this study, we showed that ascorbate at pharmacologic concentrations was a prooxidant, generating hydrogen-peroxide-dependent cytotoxicity toward a variety of cancer cells in vitro without adversely affecting normal cells. To test this action in vivo, normal oral tight control was bypassed by parenteral ascorbate administration. Real-time microdialysis sampling in mice bearing glioblastoma xenografts showed that a single pharmacologic dose of ascorbate produced sustained ascorbate radical and hydrogen peroxide formation selectively within interstitial fluids of tumors but not in blood. Moreover, a regimen of daily pharmacologic ascorbate treatment significantly decreased growth rates of ovarian ( $P < 0.005$ ), pancreatic ( $P < 0.05$ ), and glioblastoma ( $P < 0.001$ ) tumors established in mice. Similar pharmacologic concentrations were readily achieved in humans given ascorbate intravenously. These data suggest that ascorbate as a prodrug may have benefits in cancers with poor prognosis and limited therapeutic options.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516281/>

*This next study released late 2017 showed that increased dietary levels of antioxidants such as vitamin C, E,  $\beta$ -carotene, and selenium are associated with lower risk of developing colon cancer. This major epidemiological (in vivo) study had a cohort of of 38,812. On the basis of the evidence, the authors*



wrote: "Healthcare professionals may promote intake of these antioxidants in healthy amounts in order to reduce the incidence of this type of malignancy."

Resource: Egnell, M., et al. (2017). **Antioxidant intake from diet and supplements and risk of digestive cancers in middle-aged adults: results from the prospective NutriNet-Santé cohort.** British Journal of Nutrition. doi:10.1017/S0007114517002392

Abstract:

The results of the study showed that increased dietary levels of antioxidants such as vitamin C, E,  $\beta$ -carotene, and selenium are associated with lower risk of developing colon cancer. This important study has demonstrated the link between antioxidants and digestive cancer risk. The harmful effects of alcohol and smoking are also apparently reduced by the intake of selenium and vitamin E, respectively. Overall, antioxidants in the diet may reduce the risk of developing gastrointestinal cancers. Healthcare professionals may promote intake of these antioxidants in healthy amounts in order to reduce the incidence of this type of malignancy.

<https://www.ncbi.nlm.nih.gov/pubmed/28927476>

Linus Pauling and his associate, Ewan Cameron, MD, did not claim that vitamin C cured cancer, only that it extended lives making the patient feel better. This Korean study supports the Pauling /Cameron claim of longer and better lives for terminal cancer patients.

J Korean Med Sci. 2007 Feb;22(1):7-11.

**Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration.**

Yeom CH1, Jung GC, Song KJ.

Abstract

Over the years there has been a great deal of controversy on the effect of vitamin C on cancer. To investigate the effects of vitamin C on cancer patients' health-related quality of life, we prospectively studied 39 terminal cancer patients. All patients were given an intravenous administration of 10 g vitamin C twice with a 3-day interval and an oral intake of 4 g vitamin C daily for a week. And then we investigated demographic data and assessed changes in patients' quality of life after administration of vitamin C. Quality of life was assessed with EORTC QLQ-C30. In the global health/quality of life scale, health score improved from 36 $\pm$ 18 to 55 $\pm$ 16 after administration of vitamin C (p=0.001). In functional scale, the patients reported significantly higher scores for physical, role, emotional, and cognitive function after administration of vitamin C

( $p < 0.05$ ). In symptom scale, the patients reported significantly lower scores for fatigue, nausea/vomiting, pain, and appetite loss after administration of vitamin C ( $p < 0.005$ ). The other function and symptom scales were not significantly changed after administration of vitamin C. In terminal cancer patients, the quality of life is as important as cure. Although there is still controversy regarding anticancer effects of vitamin C, the use of vitamin C is considered a safe and effective therapy to improve the quality of life of terminal cancer patients.

PMID:17297243

PMCID: PMC2693571

10.3346/jkms.2007.22.1.7

<https://www.ncbi.nlm.nih.gov/pubmed/17297243>

## Resources

Stem cells, cancer, and cancer stem cells, Tannishtha Reya, Sean J. Morrison, Michael F. Clarke & Irving L. Weissman, *Nature* 414, 105-111 (1 November 2001) | doi:10.1038/35102167

Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs), Utsav Sen, Sudheer Shenoy P, Bipasha Bose, *Cell Biol Int.* 2017 Oct;41(10):1127-1145. doi: 10.1002/cbin.10830. Epub 2017 Aug 24.

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs), Ernestina Marianna De Francesco, Gloria Bonuccelli, Marcello Maggiolini, Federica Sotgia and Michael P. Lisanti, *Oncotarget.* 2017; 8:67269-67286. <https://doi.org/10.18632/oncotarget.18428>

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease, Rebecca Lamb, Bela Ozsvari<sup>1\*</sup>, Camilla L. Lisanti, Herbert B. Tanowitz, Anthony Howell, Ubaldo E. Martinez-Outschoorn, Federica Sotgia and Michael P. Lisanti, *Oncotarget.* 2015; 6:4569-4584. <https://doi.org/10.18632/oncotarget.3174>

Ascorbate regulates haematopoietic stem cell function and leukaemogenesis, Agathocleous M, Meacham CE, Burgess RJ, Piskounova E, Zhao Z, Crane GM, Cowin BL, Bruner E, Murphy MM, Chen W, Spangrude GJ, Hu Z, DeBerardinis RJ, Morrison SJ. *Nature.* 2017 Sep 28;549(7673):476-481. doi: 10.1038/nature23876. Epub 2017 Aug 21. PMID: 28825709

Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression, Cimmino, Luisa; Dolgalev, Igor; Wang, Yubao; Yoshimi, Akihide; Martin, Gaelle H; Wang, Jingjing; Ng, Victor; Xia, Bo; Witkowski, Matthew T; Mitchell-Flack, Marisa; Grillo, Isabella; Bakogianni, Sofia; Ndiaye-Lobry, Delphine; Martin, Miguel Torres. *Cell.* 2017 Aug 17; 170(6):1079-1095.e20

Glycohaemoglobin and ascorbic acid, Cheryl A Krone, John A Ely, Journal of the New Zealand Medical Association, 23-August-2002, Vol 115 No 1160.

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Qi Chen, Michael Graham Espey, Andrew Y. Sun, Chaya Pooput, Kenneth L. Kirk, Murali C. Krishna, Deena Beneda Khosh, Jeanne Drisko, and Mark Levine, Proc Natl Acad Sci U S A. 2008 Aug 12; 105(32):11105–11109.

Published online 2008 Aug 4. doi: 10.1073/pnas.0804226105

PMCID: PMC2516281

Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration, Yeom CH1, Jung GC, Song KJ., J Korean Med Sci. 2007 Feb;22(1):7-11.

## **More References**

Egnell, M., et al. (2017). Antioxidant intake from diet and supplements and risk of digestive cancers in middle-aged adults: results from the prospective NutriNet-Santé cohort. *British Journal of Nutrition*. doi:10.1017/S0007114517002392

Ma, Y., Sullivan, G. G., Schrick, E., Choi, I.-Y., He, Z., Lierman, J., ... Chen, Q. (2013). A Convenient Method for Measuring Blood Ascorbate Concentrations in Patients Receiving High-Dose Intravenous Ascorbate. *Journal of the American College of Nutrition*, 32(3), 187–193. <http://doi.org/10.1080/07315724.2013.791167>

Bürzle M, Hediger MA. (2012). Functional and physiological role of vitamin C transporters. *Curr Top Membr*, 70:357-75.

Corti A., Casini A. F., Pompella A. (2010). Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. *Archives of Biochemistry and Biophysics*, 500(2):107–115. doi: 10.1016/j.abb.2010.05.014.

Szarka A, Lőrincz T. (2013). Cellular and intracellular transport of vitamin C. The physiologic aspects. *Orv Heti*, 154(42):1651-6. doi: 10.1556/OH.2013.29712.

Fonorow, O., Unexpected Early Response in Oral Bioavailability of Vitamin C, The Townsend Letter for Doctors and Patients, July 2017.

Fonorow, O. (2015, June 15). Bioavailability of Vitamin C Data. Retrieved from <http://vitaminc.foundation/forum/viewtopic.php?f=3&t=11944>

Hickey, S., & Roberts, H. (2004). *Ascorbate: The science of vitamin C*. Morrisville, NC: Lulu.

Hickey, S., & Roberts, H. (2005). *Ridiculous Dietary Allowance*. Lulu.com.

Levine M., Conry-Cantilena C., Wang Y. (1996). Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc Natl Acad Sci*, 93(8):3704–3709.

Levine M, Padayatty SJ, Espey MG. (2011). Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. *Adv Nutr*, 2:78–88.

Chen P., Stone J., Sullivan G., Drisko J. A., Chen Q. (2011). Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. *Free Radical Biology and Medicine*, 51(3):681–687. doi: 10.1016/j.freeradbiomed.2011.05.031.

Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., ... Levine, M. (2012). Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. *PLoS ONE*, 7(1), e29794. <http://doi.org/10.1371/journal.pone.0029794>

Wang G, Yin T, Wang Y. (2016). In vitro and in vivo assessment of high-dose vitamin C against murine tumors. *Exp Ther Med*, (12):3058–3062.

Leekha A, Gurjar BS, Tyagi A, Rizvi MA, Verma AK. (2016). Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. *J Cancer Res Clin Oncol*, 142(12):2503-2514.

Baek MW, Cho HS, Kim SH, Kim WJ, Jung JY. (2017). Ascorbic Acid Induces Necrosis in Human Laryngeal Squamous Cell Carcinoma via ROS, PKC, and Calcium Signaling. *J Cell Physiol*, 232(2):417-425. doi: 10.1002/jcp.25438.

Campbell EJ, Vissers MC, Wohlrab C, Hicks KO, Strother RM, Bozonet SM, et al. (2016). Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. *Free Radic Biol Med*, 99:451–62.10.1016/j.freeradbiomed.2016.08.027

FRAJESE, G. V., BENVENUTO, M., FANTINI, M., AMBROSIN, E., SACCHETTI, P., MASUELLI, L., ... BEI, R. (2016). Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro. *Oncology Letters*, 11(6), 4224–4234. <http://doi.org/10.3892/ol.2016.4506>

Aguilera, O., Muñoz-Sagastibelza, M., Torrejón, B., Borrero-Palacios, A., del Puerto-Nevado, L., Martínez-Useros, J., ... García-Foncillas, J. (2016). Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. *Oncotarget*, 7(30), 47954–47965. <http://doi.org/10.18632/oncotarget.10087>

Jung S-A, Lee D-H, Moon J-H, Hong S-W, Shin J-S, Hwang IY, et al. (2016). L-Ascorbic acid can abrogate SVCT2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells. *Free Radic Biol Med*, 95:200–8. doi: 10.1016/j.freeradbiomed.2016.03.009

Chung MK, Kim do H, Ahn YC, Choi JY, Kim EH, Son YI. (2016). Randomized Trial of Vitamin C/E Complex for Prevention of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. *Otolaryngol Head Neck Surg*, 155(3):423-30. doi: 10.1177/0194599816642418.

Zhao F, Wang YF, Song L, Jin JX, Zhang YQ, Gan HY, Yang KH. (2017). Synergistic Apoptotic Effect of D-Fraction From *Grifola frondosa* and Vitamin C on Hepatocellular Carcinoma SMMC-7721 Cells. *Integr Cancer Ther*, 16(2):205-214. doi: 10.1177/1534735416644674.21. Parrow, N. L., Leshin, J. A., & Levine, M. (2013). Parenteral Ascorbate As a Cancer Therapeutic: A Reassessment Based on Pharmacokinetics. *Antioxidants & Redox Signaling*, 19(17), 2141–2156. <http://doi.org/10.1089/ars.2013.5372>

Cathcart R.F. (1981). Vitamin, C.; titrating to bowel tolerance, anascorbemia, and acute induced scurvy. *Med. Hypotheses*, 7:1359–1376. doi: 10.1016/0306-9877(81)90126-2.